Dental products manufacturer ZimVie will be acquired by an affiliate of healthcare-focused investment firm Archimed for $730 million.
The deal is expected to close by the end of 2025, pending shareholder and regulatory approval. Shareholders will receive $19 in cash per share. Once completed, ZimVie will become a private company, and its shares will no longer be traded on Nasdaq.
